ForbesGene Editing with CRISPR-Cas9: The Next Step in Human Evolution to be Worth 25 Billion by 2030ForbesCRISPR-Cas9 tools have recently created a buzz in the global healthcare industry, with the development of numerous applications-focused solutions—… Continue reading
Genetic Engineering & Biotechnology NewsNovel Finding on Memory T Cells May Provide Boost to Cancer ImmunotherapyGenetic Engineering & Biotechnology NewsThe finding provides insight that should help researchers design more effective vaccines and expand… Continue reading
Xconomy |
Ginkgo Bioworks Pulls In $275M as Synthetic Biology Funding Soars
Xconomy Companies sometimes raise big venture capital rounds to invest in equipment, people, and other tools for growth. Other times they do it to provide the business a cash cushion. And sometimes it’s about giving potential customers and partners more … The Latest “Unicorn” Genetically Engineers Everything From Perfume To FoodBuzzFeed News Ginkgo Bioworks Launches New Organism Foundry, Supported by $275 Million in Series D FundingPR Newswire (press release) Ginkgo Bioworks raises $275 million to bring its lab-made DNA to more industriesVentureBeat |
Xconomy |
Ginkgo Bioworks Pulls In $275M as Synthetic Biology Funding Soars
Xconomy Companies sometimes raise big venture capital rounds to invest in equipment, people, and other tools for growth. Other times they do it to provide the business a cash cushion. And sometimes it’s about giving potential customers and partners more … The Latest “Unicorn” Genetically Engineers Everything From Perfume To FoodBuzzFeed News Ginkgo Bioworks Launches New Organism Foundry, Supported by $275 Million in Series D FundingPR Newswire (press release) Ginkgo Bioworks raises $275 million to bring its lab-made DNA to more industriesVentureBeat |
Labiotech.eu (blog) |
German Biotech’s Gene Therapy for Osteoarthritis Plucked by US Pharma
Labiotech.eu (blog) GeneQuine’s gene therapy for osteoarthritis in the knee has been acquired by US pharma company Flexion Therapeutics for up to $64M. GeneQuine is developing a gene therapy for the treatment of osteoarthritis. It uses helper-dependent adenoviruses, which … |